FEB 03, 2021
Lacrimal Disorders, Oculoplastics/Orbit, Optic Neuropathy
In this interview, Drs. Julian Perry and Catherine Hwang discuss the use of intralesional rituximab to treat idiopathic dacryoadenitis. Outcomes from a 7-year study indicate that 19 patients who received rituximab showed resolution after 4 weeks of treatment. Orbital inflammation scores declined significantly. Two patients relapsed, but repeat treatment led to resolution.
Relevant Financial Disclosures: None